Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Reports 9M 2024 net sales DKK 204.72B vs. DKK 166.4B last year. Lars Fruergaard Jorgensen, president and CEO, said: “We are pleased with ...

For the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER. Growth reported in Danish kroner is now expected to be 1 ...

ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 milligrams in adults with MASH ...

Within R&D, we are very pleased about further read-outs across our semaglutide portfolio, including the SOUL trial in people living with diabetes and cardiovascular disease and the ESSENCE trial ...